Cefuroxime
Cefuroxime is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please sign in or purchase a subscription.
Pediatrics Centralâ„¢ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Uncomplicated urinary tract infections caused by E. coli or K. pneumoniae (PO and IV)
- Uncomplicated skin and skin-structure infections caused by S. aureus or S. pyogenes (PO and IV) E. coli, Klebsiella spp., and Enterobacter spp. (IV)
- Impetigo (pediatric patients) (PO)
- Upper respiratory tract infections including acute otitis media, acute maxillary sinusitis, acute exacerbation of chronic bronchitis, and pharyngitis/tonsillitis (PO)
- Early Lyme disease (erythema migrans) caused by B. burgdorferi (PO)
- Lower respiratory tract infections including community-acquired pneumonia (CAP, IV)
- Septicemia caused by S. aureus, S. pneumoniae, E. coli, H. influenzae, Klebsiella spp. (IV only)
- Meningitis S. pneumoniae, H. influenzae, N. meningitidis, and S. aureus (MSSA) (IV only).
- Author’s comment: nafcillin preferred for MSSA meningitis.
- Bone and joint infections caused by MSSA (IV)
- Uncomplicated urethral and endocervical gonorrhea and ano-rectal gonorrhea (females) caused by N. gonorrhoeae (no longer recommended, oral and IV)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Late Lyme arthritis
- CAP (oral cefuroxime)
-- To view the remaining sections of this topic, please sign in or purchase a subscription --